Drugs that contain Suvorexant

1. List of Belsomra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
M (M) Jan 29, 2023

Market Authorisation Date: 13 August, 2014

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

BELSOMRA family patents

12

United States

4

Australia

4

Russia

4

China

4

Japan

3

Korea, Republic of

3

European Union

2

Mexico

2

Argentina

2

Brazil

2

Chile

2

Taiwan, Province of China

2

Ukraine

2

Canada

1

South Africa

1

Denmark

1

El Salvador

1

Hong Kong

1

Slovenia

1

Morocco

1

Norway

1

Costa Rica

1

Colombia

1

Croatia

1

Honduras

1

Portugal

1

Cyprus

1

Malaysia

1

Spain

1

Peru

1

Poland

1

Dominican Republic

1

RS

1

Ecuador

1

Nicaragua

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in